Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primates
Victoria Koch(Roche (Switzerland)), Sven Kronenberg(Roche (Switzerland)), Elisabeth Husar(Roche (Switzerland)), Kay Stubenrauch(Roche (Switzerland)), Timothy P. Hickling(Roche (Switzerland)), Matthias Füth(Roche (Switzerland)), Katharine Bray‐French(Roche (Switzerland)), Niels Janssen(Roche (Switzerland)), Anneliese Schneider(Roche (Switzerland)), Martin Lechmann(Roche (Switzerland))
Cited by 2
Related Papers
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection
|Proceedings of the National Academy of Sciences|2003|170
Immunopurification and Mass Spectrometric Quantification of the Active Form of a Chimeric Therapeutic Antibody in Human Serum
|Analytical Chemistry|2008|144
Vaccination trial with HPV16 L1E7 chimeric virus‐like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3)
|International Journal of Cancer|2007|136
Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate
|Gastroenterology|1999|120